Obicetrapib (1) – Ubeslo®

Primary hypercholesterolaemia or mixed dyslipidaemia

Characteristics

Start date 15.11.2026
Resolution 05.05.2027 – active procedure
INN Obicetrapib
Brand name Ubeslo®
Pharm. company Berlin-Chemie AG/Menarini Group
G-BA Procedure ID D-1392
Therapeutic area Metabolic diseases
Reason for procedure Initial assessment

Associated procedures

Obicetrapib (1) Ubeslo® Berlin-Chemie AG/Menarini Group Metabolic diseases Primary hypercholesterolaemia or mixed dyslipidaemia n.d. active procedure


<< List of all resolutions